Top

Published in:

01-08-2018 | Original Paper

Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications

Authors: Kevin M. Bozymski, Jessica A. Whitten, Mary E. Blair, Ashley M. Overley, Carol A. Ott

Published in: Community Mental Health Journal | Issue 6/2018

Abstract

Antipsychotic medications carry an established lifetime risk of metabolic syndrome. This retrospective chart review evaluated feasibility of a metabolic monitoring clinical decision support tool (CDST) for weight, lipid, blood glucose, and blood pressure management of 163 clients in an early psychosis outpatient clinic over 2 years. Each parameter had at least 98 (60.1%) clients with a recorded value, the most being documented for weight with 112 (68.7%) clients. CDST adherence ranged from at least 54.3–100% for non-pharmacologic interventions (e.g. clinic counseling, referral to health program or primary care) and at least 33.3–100% for pharmacologic interventions (e.g. metformin). Though no baseline cardiometabolic abnormalities were identified, dyslipidemia and obesity were later found in 37 (22.7%) and 35 (21.5%) clients, respectively. Only 14 (8.6%) clients were prescribed medications for cardiometabolic abnormalities by psychiatrists in the clinic. Increasing focus on physical health is needed to better this population’s long-term prognosis.

American Diabetes Association. (2016). Standards of medical care in diabetes—2016. Diabetes Care, 39(Suppl 1), S1–S112.

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 272(2), 596–601.

Archie, S., Zangeneh-Kazemi, A., & Akhtar-Danesh, N. (2015). First-episode affective psychosis and lipid monitoring: Survival analysis of the first abnormal lipid test. Early Intervention in Psychiatry, 9(6), 507–511.CrossRefPubMed

Balotsev, R., Haring, L., Koido, K., Leping, V., Kriisa, K., Zilmer, M., … Vasar, E. (2017). Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12457.PubMedCrossRef

Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., … Schizophrenia Patient Outcomes Research Team (PORT). (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 71–93.CrossRefPubMed

Carney, R., Bradshaw, T., & Yung, A. R. (2015). Monitoring of physical health in services of young people at ultra-high risk of psychosis. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12288.PubMedPubMedCentralCrossRef

Carney, R., Cotter, J., Bradshaw, T., Firth, J., & Yung, A. R. (2016). Cardiometabolic risk factors in young people at ultra-high risk for psychosis: A systematic review and meta-analysis. Schizophrenia Research, 170(2–3), 290–300.CrossRefPubMed

Cooper, S. J., Reynolds, G. P., Barnes, T. R. E., England, E., Haddad, P. M., Heald, A., … Smith, J. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 30(8), 717–748.CrossRefPubMed

Cormac, I., Martin, D., & Ferriter, M. (2004). Improving the physical health of long-stay psychiatric in-patients. Advances in Psychiatric Treatment, 10(2), 107–115.CrossRef

Correll, C. U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA: The Journal of the American Medical Association, 302(16), 1765–1773.CrossRefPubMed

Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., … Kane, J. M. (2014). Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study. JAMA Psychiatry, 71(12), 1350–1363.CrossRefPubMed

Cotes, R. O., Fernandes, N. K., McLaren, J. L., McHugo, G. J., Bartels, S. J., & Brunette, M. F. (2017). Improving cardiometabolic outcomes of children on antipsychotics. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2017.0034.PubMedCrossRef

Crabb, J., McAllister, M., & Blair, A. (2009). Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team. Early Intervention in Psychiatry, 3(4), 312–316.CrossRefPubMed

De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26(3), 144–158.CrossRefPubMed

Edelsohn, G. A., Parthasarathy, M., Terhorst, L., Karpov, I. O., & Schuster, J. (2015). Measurement of metabolic monitoring in youth and adult Medicaid recipients prescribed antipsychotics. Journal of Managed Care and Specialty Pharmacy, 21(9), 769–777.CrossRefPubMed

Garcia-Rizo, C., Casanovas, M., Fernandez-Egea, E., Oliveira, C., Mesequer, A., Cabrera, B., … Bernardo, M. (2017). Blood cell count in antipsychotic-naive patients with non-affective psychosis. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12456.PubMedCrossRef

Gohlke, J. M., Dhurandhar, E. J., Correll, C. U., Morrato, E. H., Newcomer, J. W., Remington, G., … Allison, D. B. (2012). Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Frontiers in Psychiatry, 3, 62.CrossRefPubMedPubMedCentral

Gothefors, D., Adolfsson, R., Attvall, S., Erlinge, D., Jarbin, H., Lindstrom, K., … Swedish Psychiatric Association. (2010). Swedish clinical guidelines: Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nordic Journal of Psychiatry, 64(5), 294–302.CrossRefPubMed

Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. American Heart Journal, 150(6), 1115–1121.CrossRefPubMed

Horsdal, H. T., Benros, M. E., Kohler-Forsberg, O., Krogh, J., & Gasse, C. (2017). Metabolic profile at first-time schizophrenia diagnosis: A population-based cross-sectional study. Neuropsychiatric Disease and Treatment, 13, 621–630.CrossRefPubMedPubMedCentral

Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., … Brown, W. V. (2015). National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – full report. Journal of Clinical Lipidology, 9(2), 129–169.CrossRefPubMed

James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., … Ortiz, E. (2014). 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA: The Journal of the American Medical Association, 311(5), 507–520.CrossRefPubMed

Jensen, K. G., Correll, C. U., Ruda, D., Klauber, D. G., Stentebjerg-Olesen, M., Fagerlund, B., … Pagsberg, A. K. (2017). Pretreatment cardiometabolic status in youth with early-onset psychosis: Baseline results from the TEA trial. Journal of Clinical Psychiatry. https://doi.org/10.4088/JCP.15m10479.CrossRefPubMed

Lambert, T. J., Chapman, L. H. & Consensus Working Group. (2004). Diabetes, psychotic disorders, and antipsychotic therapy: A consensus statement. Medical Journal of Australia, 181(10), 544–548.PubMed

Lederman, O., Rosenbaum, S., Maloney, C., Curtis, J., & Ward, P. B. (2017). Modifiable cardiometablic risk factors in youth with at-risk mental states: A cross-sectional pilot study. Psychiatry Research. https://doi.org/10.1016/j.psychres.2017.08.034.PubMedCrossRef

Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2067–2071.CrossRef

Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70(7), 663–671.CrossRefPubMedPubMedCentral

Misiak, B., Wisniewski, J., Fleszar, M. G., & Frydecka, D. (2016). Alterations in L-arginine metabolism in first-episode schizophrenia patients: Further evidence for early metabolic dysregulation. Schizophrenia Research, 178(1–3), 56–57.CrossRefPubMed

Morrato, E. H., Nicol, G. E., Maahs, D., Druss, B. G., Hartung, D. M., Valuck, R. J., … Newcomer, J. W. (2010). Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine, 164(4), 344–351.CrossRefPubMed

Mueser, K. T., Penn, D. L., Addington, J., Brunette, M. F., Gingerich, S., Glynn, S. M., … Kane, J. M. (2015). The NAVIGATE program for first-episode psychosis: Rationale, overview, and description of psychosocial components. Psychiatric Services, 66(7), 680–690.CrossRefPubMed

Murray, J., Baillon, S., Bruce, J., & Velayudhan, L. (2015). A survey of psychiatrists’ attitudes toward the physical examination. Journal of Mental Health, 24(4), 249–254.CrossRefPubMed

National Cholesterol Education Program. (2002). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation, 106(25), 3143–3421.CrossRef

National Institutes of Health, & National Heart, Lung, and Blood Institute. (1998). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: The evidence report. Obesity Research, 6(Suppl 2), 51S–209S.

O’Donoghue, B., Schafer, M. R., Becker, J., Papageorgiou, K., & Amminger, G. P. (2014). Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Intervention in Psychiatry, 8(3), 276–280.CrossRefPubMed

Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172–1181.CrossRefPubMed

Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia-Unzueta, M. T., Ramirez-Bonilla, M. L., Gonzalez-Blanch, C., … Vazquez-Barquero, J. L. (2007). A 12-week randomized clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. Journal of Clinical Psychiatry, 68(11), 1733–1740.CrossRefPubMed

Perez-Iglesias, R., Mata, I., Pelayo-Teran, J. M., Amado, J. A., Garcia-Unzueta, M. T., Berja, A., … Crespo-Facorro, B. (2009). Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. Schizophrenia Research, 107(2–3), 115–121.CrossRefPubMed

Petrikis, P., Tigas, S., Tzallas, A. T., Papadopoulos, I., Skapinakis, P., & Mavreas, V. (2015). Parameters of glucose and lipid metabolism at the fasted state in drug-naïve first-episode patients with psychosis: Evidence for insulin resistance. Psychiatry Research, 229(3), 901–904.CrossRefPubMed

Pillinger, T., Beck, K., Gobjila, C., Donocik, J. G., Jauhar, S., & Howes, O. D. (2017). Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry, 74(3), 261–269.CrossRefPubMed

Pringsheim, T., Panagiotopoulos, C., Davidson, J., Ho, J. & Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) guideline group. (2011). Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 16(9), 581–589.CrossRefPubMed

Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008). Metabolic syndrome in first episode schizophrenia: A randomized double-blind controlled, short-term prospective study. Schizophrenia Research, 101(1–3), 266–272.CrossRefPubMed

Schneiderhan, M. E., Batscha, C. L., & Rosen, C. (2009). Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. Pharmacotherapy, 29(8), 975–987.CrossRefPubMed

Thompson, A., Hetrick, S. E., Alvarez-Jiménez, M., Parker, A. G., Willet, M., Hughes, F., … McGorry, P. D. (2011). Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Australian and New Zealand Journal of Psychiatry, 45(9), 740–748.CrossRefPubMed

Woo, V., Harris, S. B., & Houlden, R. L. (2005). Canadian Diabetes Association position paper: Antipsychotic medications and associated risks of weight gain and diabetes. Canadian Journal of Diabetes, 29, 111–112.

Title: Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications
Authors: Kevin M. Bozymski
Jessica A. Whitten
Mary E. Blair
Ashley M. Overley
Carol A. Ott
Publication date: 01-08-2018
Publisher: Springer US
Published in: Community Mental Health Journal / Issue 6/2018
Print ISSN: 0010-3853
Electronic ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-017-0203-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Monitoring and Treating Metabolic Abnormalities in Patients with Early Psychosis Initiated on Antipsychotic Medications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Impact of a Pilot Videogame-Based Physical Activity Program on Walking Speed in Adults with Schizophrenia

Reasons for Nonadherence to Psychiatric Medication and Cardiovascular Risk Factors Treatment Among Latino Bipolar Disorder Patients Living in Puerto Rico: A Qualitative Study

Acceptability of Mental Health Services for Anxiety and Depression in an Arab Sample

Mental Health in China: Stigma, Family Obligations, and the Potential of Peer Support

Correction to: Mental Health in China: Stigma, Family Obligations, and the Potential of Peer Support

Emergency Department Staff Beliefs About Self-Harm: A Thematic Framework Analysis